Celgene Corp. said Tuesday it is ending a late-stage clinical study of its drug Revlimid as a treatment for prostate cancer.
Celgene said an early analysis of data showed that patients who were treated with Revlimid were not living longer than patients who took a placebo. The patients had prostate cancer that did not respond to hormone therapy, and they were all treated with the cancer drug Taxotere and prednisone in addition to Revlimid or the placebo.
Revlimid, or lenalidomide, is approved as a treatment for multiple myeloma, a cancer that affects plasma cells in bone marrow, and for one type of the bone barrow disease myelodysplastic syndrome. Celgene is also studying the drug as a treatment for several other cancers, including non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
Shares of Celgene rose 37 cents to $61.69 on Tuesday. They were unchanged in extended trading following the company's statement about Revlimid.